OncoMatch/Clinical Trials/NCT05863234

Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Is NCT05863234 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies PPMX-T003 for aggressive nk cell leukemia.

Phase 1/2RecruitingHiroshima University HospitalNCT05863234Data as of May 2026

Treatment: PPMX-T003 — This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify